Development And Validation Of HPLC Method For The Determination Of Suvorexant In Pharmaceutical Dosage Forms
Keywords:Suvorexant; Insomnia; Neurokinin receptor; HPLC, MK-4305, Orexin Receptor
The present experiment was focused in developing an accurate and precise method for the estimation of Suvorexant in pharmaceutical Tablet dosage form. The mobile phase consisted of 65:35 % (v/v) of Methanol & 0.1% orthophosphoric acid solution operated on isocratic mode. The flow rate is 1.0 ml/min. Chromatographic determination of Suvorexant was performed on Agilent Zorbax 300oA Extend-C18 column (150 X 4.6 mm id, 5µm). The wavelength of detection is 248 nm. The injection volume is 20µL. The retention time of Suvorexant is 5.50 ± 0.10 minutes. The method was validated as per ICH guidelines and has been successfully used for the estimation in tablet dosage forms.
Brisbare-Roch, C., Dingemanse, J., Koberstein, R., Hoever, P., Aissaoui, H., Flores, S., et al. (2007). Pro-motion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med, 13 , 150 – 155.
Z. Ahmed, A. Ahmad, S.A. Khan, A. Husain, Pharmacological, pharmaceutical and safety profile of suvorexant: a dual orexin receptors antagonist for treatment of insomnia, Int. Educ. Sci. Res. J. 1 (2015) 26–30.
T. Bennett, D. Bray, M.W. Neville, Suvorexant, a dual orexin receptor antagonist for the management of insomnia, Pharm. Ther. 39 (2014) 264–266.
L.H. Yang, Suvorexant: first global approval, Drugs 74 (2014) 1817–1822.
K.V. Patel, A.V. Aspesi, K.E. Evoy, Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia, Ann. Pharmacother. 49 (2015) 477–483.
S.A. Breidinger, R.C. Simpson, E. Mangin, E.J. Woolf, Determination of suvorexant in human plasma using 96-well liquid-liquid extraction and HPLC with tandem mass spectrometric detection, J. Chromatogr. B Analyt. Technol.Biomed. Life Sci. 1002 (2015) 254–259.
D. Cui, T. Cabalu, K. Lai Yee, J. Small, X. Li, B. Liu, C. Maciolek, S. Smith, W. Liu,J.B. McCrea, T. Prueksaritanont, In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans, Xenobiotica (2016)1–14.
H. Sun, W.P. Kennedy, D. Wilbraham, N. Lewis, N. Calder, X. Li, J. Ma, K.L. Yee,S. Ermlich, E. Mangin, C. Lines, L. Rosen, J. Chodakewitz, G.M. Murphy, Effects of suvorexant an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men, Sleep 36 (2013) 259–267.
Mariah Carson, Sarah Kerrigan; Quantification of suvorexant in urine using gas chro-matography/mass spectrometry Journal of Chromatography B, 1040 (2017) 289–294.
International Conference on Harmonization (ICH), Validation of Analytical Procedures: Text and Methodology Q2 (R1), November 2005.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.